Neuphoria Therapeutics Inc.
For the period ended Mar 31, 2026. Filed May 15, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 15, 2026
NEUP$2.76-0.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Changes in Shareholders' Equity
Condensed Consolidated State ments of Changes in Shareholders' Equity (Unaudited)
| Stock · Additional · AccumulatedOther · Total | ||||||||
|---|---|---|---|---|---|---|---|---|
| Common Shares · Subscription · Paid-In · Comprehensive · Accumulated · Shareholders' | ||||||||
| Shares · Amount · Receivable · Capital · Loss · Deficit · Equity | ||||||||
| Balance at June 30, 2025 | 1,978,460 | $19 | $(94,685) | $200,289,009 | $(2,845,066) | $(178,346,703) | $19,002,574 | |
| Issuance of common stock in connection with our ATM facility, net of offering costs of $0.1 million | 379,153 | 4 | - | 3,158,930 | - | - | 3,158,934 | |
| Collection of subscription receivable | - | - | 94,685 | - | - | - | 94,685 | |
| Share-based compensation | - | - | - | 111,277 | - | - | 111,277 | |
| Other comprehensive income | - | - | - | - | 49,221 | - | 49,221 | |
| Net loss | - | - | - | - | - | (9,906,504) | (9,906,504) | |
| Balance at September 30, 2025 | 2,357,613 | $23 | $ | - | $203,559,216 | $(2,795,845) | $(188,253,207) | $12,510,187 |
| Issuance of common stock in connection with our ATM facility, net of offering costs of $0.5 million | 3,019,716 | 31 | - | 14,662,233 | - | - | 14,662,264 | |
| Share-based compensation | - | - | - | 93,701 | - | - | 93,701 | |
| Other comprehensive income | - | - | - | - | 570,580 | - | 570,580 | |
| Net income | - | - | - | - | - | 1,864,092 | 1,864,092 | |
| Balance at December 31, 2025 | 5,377,329 | $54 | $ | - | $218,315,150 | $(2,225,265) | $(186,389,115) | $29,700,824 |
| Share-based compensation | - | - | - | 70,286 | - | - | 70,286 | |
| Other comprehensive income | - | - | - | - | 157,897 | - | 157,897 | |
| Net loss | - | - | - | - | - | (505,063) | (505,063) | |
| Balance at March 31, 2026 | 5,377,329 | $54 | $ | - | $218,385,436 | $(2,067,368) | $(186,894,178) | $29,423,944 |
| Balance at June 30, 2024 | 1,103,954 | $11 | $ | - | $198,481,027 | $(3,013,595) | $(177,977,071) | $17,490,372 |
| Exercise of pre-funded ADS warrants | 339,408 | 3 | - | 406 | - | - | 409 | |
| Share issue costs | - | - | - | (227,747) | - | - | (227,747) | |
| Share-based compensation | - | - | - | 26,736 | - | - | 26,736 | |
| Other comprehensive income | - | - | - | - | 585,381 | - | 585,381 | |
| Net loss | - | - | - | - | - | (804,787) | (804,787) | |
| Balance at September 30, 2024 | 1,443,362 | $14 | $ | - | $198,280,422 | $(2,428,214) | $(178,781,858) | $17,070,364 |
| Exercise of pre-funded ADS warrants | 185,297 | 2 | - | 218 | - | - | 220 | |
| Share issue costs | - | - | - | (111,777) | - | - | (111,777) | |
| Share-based compensation | - | - | - | 20,970 | - | - | 20,970 | |
| Other comprehensive loss | - | - | - | - | (1,288,433) | - | (1,288,433) | |
| Net loss | - | - | - | - | - | (1,943,349) | (1,943,349) | |
| Balance at December 31, 2024 | 1,628,659 | $16 | $ | - | $198,189,833 | $(3,716,647) | $(180,725,207) | $13,747,995 |
| Issuance of ADS shares, net of issuance costs of $0.1 million | 225,307 | 3 | - | 1,162,501 | - | - | 1,162,504 | |
| Share-based compensation | - | - | - | 20,466 | - | - | 20,466 | |
| Other comprehensive loss | - | - | - | - | (195,818) | - | (195,818) | |
| Net income | - | - | - | - | - | 11,262,161 | 11,262,161 | |
| Balance at March 31, 2025 | 1,853,966 | $19 | $ | - | $199,372,800 | $(3,912,465) | $(169,463,046) | $25,997,308 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.